Provide feedbackProvide feedback
Home :: Orthopedics

FDA warns of potential increase in fracture risk with PPI use, requires product label revisions

Friday, June 04 2010 | Comments
Evidence Grade 0 What's This?

Using proton pump inhibitors (PPIs) for a long-term period or at high doses could increase the risk of certain fractures, according to a warning issued by the Food and Drug Administration. The agency is requiring manufacturers of drugs in this class to revise product labels to reflect this new information. The warning applies to prescription PPI products, including esomeprazole magnesium, omeprazole, lansoprazole, dexlansoprazole, pantoprazole sodium, omeprazole/sodium bicarbonate,...

Using proton pump inhibitors (PPIs) for a long-term period or at high doses could increase the risk of certain fractures, according to a warning issued by the Food and Drug Administration. The agency is requiring manufacturers of drugs in this class to revise product labels to reflect this new information.

The warning applies to prescription PPI products, including esomeprazole magnesium, omeprazole, lansoprazole, dexlansoprazole, pantoprazole sodium, omeprazole/sodium bicarbonate, and rabeprazole sodium, among others, as well as over-the-counter (OTC) PPIs, including OTC formulations of omeprazole and lansoprazole.

The regulatory agency said the warning was based on a review of 7 epidemiological studies; in 6 of the studies, an increased risk of fractures of the hip, wrist, and/or spine was reported in patients using PPIs. Results from 2 of the studies suggested that a greater risk of fractures was observed among participants who received high doses of the agents. The FDA also noted that data from 2 of the studies demonstrated an increase in fractures when PPIs were used for a longer duration.

The increased risk in fractures was observed primarily in patients aged 50 years or older, as the majority of the studies reviewed included patients in this age group.

The FDA advised health care professionals to consider implementing treatment at a lower dose or for a shorter duration and to monitor bone status in individuals at risk for osteoporosis.

"At the present time, there is uncertainty about the magnitude of this risk," the agency noted.

The FDA is planning to analyze data from several large, long-term, placebo-controlled clinical trials of bisphosphonates to assess the risk of fractures in women at risk for osteoporosis-related fractures who did or did not use PPIs.

Latest News

FDA committee meeting on Amgen's investigational denosumab to focus on risks, benefits Verusmed

Wednesday, August 12 2009 | Comments
Evidence Grade 0 What's This?
The risks of Amgen Inc.'s investigational monoclonal antibody denosumab--especially when used as a preventative treatment for bone loss--must be weighed against its benefits, according to a Food and Drug Administration briefing document released ahead of an advisory committee meeting.

The Division of Reproductive and Urological Products is scheduled meet Thursday to discuss denosumab, which has a proposed brand...
Tags: Breast Cancer, Prostate Cancer


Probability of carpal tunnel syndrome diagnosis by clinical evaluation changes little with electrodiagnostic testing, data indicate Verusmed

Thursday, December 18 2008 | Comments
Evidence Grade 1 What's This?
After a clinical diagnosis of carpal tunnel syndrome (CTS) is made with the CTS-6 aid, conducting electrodiagnostic testing provides minimal diagnostic value to the health care professional, according to a recent study.

The prospective investigation was conducted to compare the probability of a CTS diagnosis when determined by clinical evaluation or by electrodiagnostic testing.

A total of 143 patients with any upper-extremity peripheral nerve problem first...


Laminar airflow ventilation during orthopedic, abdominal procedures does not prevent surgical site infections, study suggests Verusmed

Friday, November 07 2008 | Comments
Evidence Grade 4 What's This?
A large, retrospective study suggests that operating rooms (ORs) with laminar airflow ventilation do not prevent surgical site infections (SSIs) among patients undergoing abdominal or orthopedic surgery, and ORs with this type of ventilation may actually be associated with a significantly higher risk of severe SSIs following hip replacements as compared with ORs that use turbulent ventilation.

The study included data from 63 surgery departments in 55 German...

Hypoxemia following total joint arthroplasty may predict medical complications, researchers suggest Verusmed

Thursday, November 06 2008 | Comments
Evidence Grade 2 What's This?
Hypoxemia, as an initial presenting sign, may predict the occurence of life-threatening complications following total joint arthroplasty, a prospective study revealed.



Videos